BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38057326)

  • 1. Inhibiting stromal Class I HDACs curbs pancreatic cancer progression.
    Liang G; Oh TG; Hah N; Tiriac H; Shi Y; Truitt ML; Antal CE; Atkins AR; Li Y; Fraser C; Ng S; Pinto AFM; Nelson DC; Estepa G; Bashi S; Banayo E; Dai Y; Liddle C; Yu RT; Hunter T; Engle DD; Han H; Von Hoff DD; Downes M; Evans RM
    Nat Commun; 2023 Dec; 14(1):7791. PubMed ID: 38057326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting Stromal Class I HDACs Curbs Pancreatic Cancer Progression.
    Liang G; Oh TG; Hah N; Tiriac H; Shi Y; Truitt ML; Antal CE; Atkins AR; Li Y; Fraser C; Ng S; Pinto AFM; Nelson DC; Estepa G; Bashi S; Banayo E; Dai Y; Liddle C; Yu RT; Hunter T; Engle DD; Han H; Von Hoff DD; Downes M; Evans RM
    bioRxiv; 2023 Sep; ():. PubMed ID: 37745372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
    Roca MS; Moccia T; Iannelli F; Testa C; Vitagliano C; Minopoli M; Camerlingo R; De Riso G; De Cecio R; Bruzzese F; Conte M; Altucci L; Di Gennaro E; Avallone A; Leone A; Budillon A
    J Exp Clin Cancer Res; 2022 Mar; 41(1):83. PubMed ID: 35241126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LAMA5/ITGA4 Axis.
    Parte S; Kaur AB; Nimmakayala RK; Ogunleye AO; Chirravuri R; Vengoji R; Leon F; Nallasamy P; Rauth S; Alsafwani ZW; Lele S; Cox JL; Bhat I; Singh S; Batra SK; Ponnusamy MP
    Gastroenterology; 2024 May; 166(5):842-858.e5. PubMed ID: 38154529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors.
    Djurec M; Graña O; Lee A; Troulé K; Espinet E; Cabras L; Navas C; Blasco MT; Martín-Díaz L; Burdiel M; Li J; Liu Z; Vallespinós M; Sanchez-Bueno F; Sprick MR; Trumpp A; Sainz B; Al-Shahrour F; Rabadan R; Guerra C; Barbacid M
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1147-E1156. PubMed ID: 29351990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer.
    McAndrews KM; Chen Y; Darpolor JK; Zheng X; Yang S; Carstens JL; Li B; Wang H; Miyake T; Correa de Sampaio P; Kirtley ML; Natale M; Wu CC; Sugimoto H; LeBleu VS; Kalluri R
    Cancer Discov; 2022 Jun; 12(6):1580-1597. PubMed ID: 35348629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential.
    Knudsen ES; Balaji U; Freinkman E; McCue P; Witkiewicz AK
    Oncotarget; 2016 Nov; 7(48):78396-78411. PubMed ID: 27623078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Cell-Intrinsic p38 MAPK Signaling Promotes IL1α-Mediated Stromal Inflammation and Therapeutic Resistance in Pancreatic Cancer.
    Singh SP; Dosch AR; Mehra S; De Castro Silva I; Bianchi A; Garrido VT; Zhou Z; Adams A; Amirian H; Box EW; Sun X; Ban Y; Datta J; Nagathihalli NS; Merchant NB
    Cancer Res; 2024 Apr; 84(8):1320-1332. PubMed ID: 38285896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desmoplastic Crosstalk in Pancreatic Ductal Adenocarcinoma Is Reflected by Different Responses of Panc-1, MIAPaCa-2, PaTu-8902, and CAPAN-2 Cell Lines to Cancer-associated/Normal Fibroblasts.
    Novák Š; Kolář M; Szabó A; Vernerová Z; Lacina L; Strnad H; Šáchová J; Hradilová M; Havránek J; Španko M; Čoma M; Urban L; Kaňuchová M; Melegová N; Gürlich R; Dvořák J; Smetana K; Gál P; Szabo P
    Cancer Genomics Proteomics; 2021; 18(3):221-243. PubMed ID: 33893076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal cues regulate the pancreatic cancer epigenome and metabolome.
    Sherman MH; Yu RT; Tseng TW; Sousa CM; Liu S; Truitt ML; He N; Ding N; Liddle C; Atkins AR; Leblanc M; Collisson EA; Asara JM; Kimmelman AC; Downes M; Evans RM
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1129-1134. PubMed ID: 28096419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma.
    Zhang X; Zegar T; Weiser T; Hamdan FH; Berger BT; Lucas R; Balourdas DI; Ladigan S; Cheung PF; Liffers ST; Trajkovic-Arsic M; Scheffler B; Joerger AC; Hahn SA; Johnsen SA; Knapp S; Siveke JT
    Int J Cancer; 2020 Nov; 147(10):2847-2861. PubMed ID: 32599645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment.
    Boyd LNC; Andini KD; Peters GJ; Kazemier G; Giovannetti E
    Semin Cancer Biol; 2022 Jul; 82():184-196. PubMed ID: 33737108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
    Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
    Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system.
    Schuth S; Le Blanc S; Krieger TG; Jabs J; Schenk M; Giese NA; Büchler MW; Eils R; Conrad C; Strobel O
    J Exp Clin Cancer Res; 2022 Oct; 41(1):312. PubMed ID: 36273171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition.
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA;
    Cancer Res; 2021 Jul; 81(13):3461-3479. PubMed ID: 33980655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiological role of microRNA-29 in pancreatic cancer stroma.
    Kwon JJ; Nabinger SC; Vega Z; Sahu SS; Alluri RK; Abdul-Sater Z; Yu Z; Gore J; Nalepa G; Saxena R; Korc M; Kota J
    Sci Rep; 2015 Jun; 5():11450. PubMed ID: 26095125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer.
    Lefler JE; MarElia-Bennett CB; Thies KA; Hildreth BE; Sharma SM; Pitarresi JR; Han L; Everett C; Koivisto C; Cuitino MC; Timmers CD; O'Quinn E; Parrish M; Romeo MJ; Linke AJ; Hobbs GA; Leone G; Guttridge DC; Zimmers TA; Lesinski GB; Ostrowski MC
    Life Sci Alliance; 2022 Nov; 5(11):. PubMed ID: 35803738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.
    Shi Y; Gao W; Lytle NK; Huang P; Yuan X; Dann AM; Ridinger-Saison M; DelGiorno KE; Antal CE; Liang G; Atkins AR; Erikson G; Sun H; Meisenhelder J; Terenziani E; Woo G; Fang L; Santisakultarm TP; Manor U; Xu R; Becerra CR; Borazanci E; Von Hoff DD; Grandgenett PM; Hollingsworth MA; Leblanc M; Umetsu SE; Collisson EA; Scadeng M; Lowy AM; Donahue TR; Reya T; Downes M; Evans RM; Wahl GM; Pawson T; Tian R; Hunter T
    Nature; 2019 May; 569(7754):131-135. PubMed ID: 30996350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.